Results 131 to 140 of about 6,463,095 (311)
Progression-free and overall survival for AT-101 monotherapy in patients with recurrent glioblastoma (NABTT 0702).
Joy Fisher (17867121) +11 more
core +1 more source
, 2016 Progression-free survival according to pre-therapy and follow-up NLR at 12 weeks of enzalutamide treatment.
Lisa Derosa (2605687) +15 more
core +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Progression-free survival analysis.
, 2014 Kaplan-Meier curves for progression-free survival according to ALK status: increase of gene copy number vs. disomic status.
Ilaria Bossi (545437) +12 more
core +1 more source
Regression modelling of overall survival and progression-free survival
, 2020 There are three endpoints commonly used in oncology clinical trials, which are known as overall survival (OS), time to progression (TTP) and progression-free survival (PFS). Recently, PFS has become an important alternative endpoint to OS. In this thesis, both exponential and Weibull distributions are used to investigate the joint model of OS and PFS ...
openaire +1 more source
Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization
Molecular Oncology, EarlyView.In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu +13 more
wiley +1 more source
Median Progression-free and Overall Survival.
, 2016 Median Progression-free and Overall Survival.
Nick Pavlakis (783392) +7 more
core +1 more source
Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola +11 more
wiley +1 more source
Factors associated with progression-free survival.
, 2018 Factors associated with progression-free survival.
Jennifer Dumoulin (5131088) +6 more
core +1 more source
Progression-free survival in the ICON8 trial – Authors' reply [PDF]
The Lancet, 2020 James, EC +4 more
openaire +3 more sources